Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
The Cambridge, MA-based company was founded in 2011. It plans to list on the Nasdaq under the symbol SYRS. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
